Karyopharm Therapeutics Inc. - 8-K Filing
Karyopharm Therapeutics submitted an sNDA for XPOVIO in combination with ruxolitinib for myelofibrosis seeking Accelerated Approval (Items: 8.01 Other Events)
Tickers: $KPTI
Karyopharm Therapeutics submitted an sNDA for XPOVIO in combination with ruxolitinib for myelofibrosis seeking Accelerated Approval (Items: 8.01 Other Events)
Tickers: $KPTI